Department of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
Cancer Biother Radiopharm. 2019 Sep;34(7):427-435. doi: 10.1089/cbr.2019.2811. Epub 2019 May 21.
The advent of the Germanium-68 (Ge-68)/Gallium-68 (Ga-68) generator has contributed enormously to a plethora of molecular imaging approaches for identification of tumor characteristics. The present study compares the effect of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane,1-gluteric acid-4,7-acetic acid (NODAGA) bifunctional chelators on radiolabeling of arginine-glycine-aspartic acid (RGD) dimer, an antagonist of integrin αβ with Ga-68 and their biodistribution in C57BL/6 mice bearing melanoma and in patients with breast carcinoma. Radiolabeling parameters for DOTA-(RGD) and NODAGA-(RGD) with Ga-68 were optimized in-house. After quality control procedures, preclinical studies were done in C57BL/6 mice bearing melanoma. The percent radioactivity associated with per gram of various organs and tumor (% ID/g) was analyzed. Positron emission tomography-computed tomography patient imaging was performed in clinically diagnosed locally advanced breast carcinoma patients ( = 30). The uptake of various organs and lesions for both radiotracers was compared. Radiolabeling yield >95% was obtained by heating 15-20 μg of peptide at 95°C for 5-10 min and 3.5-4.0 reaction pH. NODAGA-(RGD) could also be radiolabeled at room temperature, but 40-50 μg peptide was required. Animal biodistribution study revealed the kidney as the major excretory organ for both the radiotracers. Maximum counts were observed in tumor at 45 min. During the clinical study, liver, spleen, bilateral brain ventricles, salivary glands, and intestines were the organs with physiological uptake of both Ga-68-DOTA-(RGD) and Ga-68 NODAGA-(RGD). The major excretory route was through kidneys. All primary lesions were picked by both the radiotracers. Additionally, in 5 patients, metastatic lesions were also picked up. DOTA- and NODAGA-chelated RGD were successfully radiolabeled with Ga-68. Good tumor to background contrast exhibited by Ga-68-DOTA-(RGD) and Ga-68 NODAGA-(RGD) in both preclinical and clinical studies suggested that both radiotracers can be used as potential molecular tools for imaging angiogenesis.
镓-68(Ga-68)/锗-68(Ge-68)发生器的出现极大地促进了多种分子成像方法的发展,用于识别肿瘤特征。本研究比较了 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)和 1,4,7-三氮杂环壬烷-1-羧酸-4,7-乙酸(NODAGA)双功能螯合剂对精氨酸-甘氨酸-天冬氨酸(RGD)二聚体进行放射性标记的效果,RGD 二聚体是整合素 αβ 的拮抗剂,与 Ga-68 结合,并在携带黑色素瘤的 C57BL/6 小鼠和患有乳腺癌的患者中进行了它们的生物分布研究。在内部优化了 DOTA-(RGD)和 NODAGA-(RGD)与 Ga-68 的放射性标记参数。经过质量控制程序后,在携带黑色素瘤的 C57BL/6 小鼠中进行了临床前研究。分析了与各种器官和肿瘤每克相关的放射性活度(% ID/g)。对 30 名临床诊断为局部晚期乳腺癌的患者进行了正电子发射断层扫描-计算机断层扫描(PET-CT)患者成像。比较了两种示踪剂在各种器官和病变中的摄取情况。通过将 15-20μg 肽在 95°C 加热 5-10min 并将反应 pH 值调节至 3.5-4.0,可获得放射性标记产率>95%。NODAGA-(RGD)也可以在室温下进行放射性标记,但需要 40-50μg 肽。动物生物分布研究表明,两种示踪剂的主要排泄器官均为肾脏。在 45min 时观察到肿瘤中最大的计数。在临床研究中,肝脏、脾脏、双侧脑室、唾液腺和肠道是 Ga-68-DOTA-(RGD)和 Ga-68-NODAGA-(RGD)具有生理摄取的器官。主要排泄途径是通过肾脏。两种示踪剂都可以检测到所有原发性病变。此外,在 5 名患者中,还检测到了转移性病变。用 Ga-68 成功标记了 DOTA 和 NODAGA 螯合的 RGD。Ga-68-DOTA-(RGD)和 Ga-68-NODAGA-(RGD)在临床前和临床研究中均表现出良好的肿瘤与背景对比度,表明这两种示踪剂均可作为成像血管生成的潜在分子工具。